CME Insider Filing: Proposed Sale of 11,896 Common Shares on NASDAQ

Rhea-AI Filing Summary

Form 144 notice for CME Group, Inc. (CME) shows a proposed sale of 11,896 common shares valued at approximately $3,229,452.32, to be executed through Morgan Stanley Smith Barney on NASDAQ on 08/26/2025. The filer acquired the shares as performance shares (2,283 shares, acquired 03/15/2025) and restricted stock (9,613 shares, acquired 09/15/2020). No securities were reported sold in the past three months. The filing includes the standard representation that the seller is unaware of undisclosed material adverse information about the issuer.

Insights

Financial Analyst

TL;DR: Routine insider notice of proposed sale; size is immaterial to outstanding common shares.

The Form 144 discloses a planned sale of 11,896 shares (~$3.23M) via a broker on NASDAQ. Against the reported 360,377,042 shares outstanding, this represents a de minimis percentage, so there is no evident market-moving dilution or governance change. The holdings were acquired as compensation (performance shares and restricted stock), which is typical for insiders monetizing vested equity. No prior sales in the last three months are reported, suggesting this is an isolated planned disposition rather than a pattern.

Compliance/Risk Analyst

TL;DR: Filing appears procedurally complete; includes seller's attestation regarding material nonpublic information.

The Form contains required acquisition details and payment nature for the securities to be sold and identifies the executing broker. The inclusion of the seller's signature attestation language aligns with Rule 144 compliance requirements and mentions the possibility of a Rule 10b5-1 plan without specifying one. No red flags or disclosures of undisclosed material information are present in the text provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	11896	3229452.32	360377042	08/26/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/15/2025	Performance Shares	Issuer			2283	03/15/2025	Not Applicable
Common	09/15/2020	Restricted Stock	Issuer			9613	09/15/2020	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the CME Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 11,896 common shares valued at approximately $3,229,452.32, to be sold on 08/26/2025 on NASDAQ through Morgan Stanley Smith Barney.

How were the shares being sold acquired according to the Form 144?

The shares were acquired as performance shares (2,283 shares on 03/15/2025) and restricted stock (9,613 shares on 09/15/2020).

Does the Form 144 report any securities sold in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

Who is the executing broker named in the filing?

The executing broker is Morgan Stanley Smith Barney LLC, Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

Does the filer assert any material nonpublic information in the notice?

By signing, the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.